METHODS: A urine sample was collected prior to cystoscopy and mutation/methylation status of 6 genes was determined in DNA from urinary cells and combined with age. This existing diagnostic model was validated on this cohort and optimized using logistic regression. Clinical usefulness was determined by the net benefit approach.
METHODS: A urine sample was collected prior to cystoscopy and mutation/methylation status of 6 genes was determined in DNA from urinary cells and combined with age. This existing diagnostic model was validated on this cohort and optimized using logistic regression. Clinical usefulness was determined by the net benefit approach.
RESULTS: In 838 patients, the mutation/methylation status could be determined for all genes. Urothelial cancer was observed in 112 patients (98/457 in the gross and 14/381 in the microscopic hematuria group) Application of the existing model resulted in an AUC of 0.93. Combining the assay with the type of hematuria resulted in the final optimal model with an AUC of 0.96 (96% sensitivity, 73% specificity, 99% negative predictive value). The assay also detected all six upper tract urothelial tumors that are not visible by cystoscopy. Net benefit analysis showed that the urine test should be preferred over 'cystoscopy for all'. Application of the optimal model on patients whose biomarker status was incomplete, resulted in the identification of 5 additional tumors. Implementing the urine test as a triage tool could lead to a 63% reduction in cystoscopies.
CONCLUSIONS: The urine test detects urothelial cancer in hematuria patients with high accuracy. It appears a simple selection tool, in particular for patients with microscopic hematuria. 
MP43-08 BCG VS CHEMOHYPERTHERMIA WITH MITOMYCIN C FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CARCINOMA: PRELIMINARY RESULTS OF HIVEC-HR RANDOMIZED CLINICAL TRIAL
F elix Guerrero-Ramos*, Daniel Antonio Gonz alez-Padilla, Alejandro Gonz alez-Díaz, Jos e Manuel Duarte-Ojeda, Natalia Miranda-Utrera, Felipe Villacampa-Aub a, Federico de la Rosa-Kehrmann, Madrid, Spain INTRODUCTION AND OBJECTIVES: After the BCG shortage happened several years ago, there is an increasing interest in finding a valid alternative for patients with non-muscle invasive bladder cancer (NMIBC). HIVEC-HR is a pilot study that aims to compare efficacy and safety between BCG and chemohyperthermia (CHT) with mitomycin C (MMC). Here we present our preliminary results once randomization has been completed.
METHODS: Open pilot randomized clinical trial 1:1 including patients with high-risk NMIBC according to EAU Guidelines (EudraCT 2016-001186-85). Patients with CIS, intolerance or contraindication for receiving BCG or MMC were excluded.
Patients were randomly assigned to one of the following groups:
-BCG (TICE strain): 50 mg diluted in 50 mL of sterile saline held for 2 hours in the bladder, one weekly instillation for 6 weeks and maintenance according to SWOG protocol.
-CHT: 40 mg MMC diluted in 40 mL of distilled water at 43 C using COMBATÒ recirculation system for 60 minutes, one weekly instillation for 6 weeks and one monthly instillation for 6 months.
Follow-up was carried out with cytology and cystoscopy every 3 months as well as upper urinary tract imaging yearly, as stated by EAU Guidelines.
Primary endpoint was recurrence-free survival at 24 months. Secondary objectives were to evaluate safety, progression rate, overall survival and quality of life.
RESULTS: Fifty patients have been randomized (100% recruitment completed), with 48 finally starting treatment. Median age is 73 years old, 87.6% were males and 83% were primary tumours. Baseline characteristics were comparable in both groups. Median follow-up is 12.3 months from TURBT.
For the BCG group, 5 recurrences and 4 progressions to T2 were reported, and only 1 progression happened in the CHT group with no recurrences (see figure) .
Regarding safety profile, adverse events (AE) appeared in 11 patients in the CHT group and 9 in the BCG group. In relation to the severity of these AEs, 4 patients in each group presented CTCAE grade 3 complications, although 3/4 in the CHT group were treatment withdrawals due to MMC allergy. More patients in the BCG group had to discontinue due to AE (6 vs 4). Four patients have died so far, none of them related with their bladder cancer.
CONCLUSIONS: According to our trial preliminary results, CHT in high risk NMIBC patients seems not to be inferior to BCG in terms of efficacy. Moreover, patients under CHT have a higher therapeutic adherence than those under BCG treatment.
Source of Funding: None.
MP43-09 PHASE I TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GU ERIN COMBINED WITH INTRAVENOUS PEMBROLIZUMAB IN HIGH GRADE NONMUSCLE INVASIVE BLADDER CANCER
Shaheen Alanee*, Detroit, MI; Ahmed El-Zawahry, Springfield, IL; kevin McVary, Maywood, IL; Mustafa Deebajah, Detroit, MI; Sherjeel Sana, Kathy Robinson, Krishna Rao, Springfield, IL INTRODUCTION AND OBJECTIVES: A phase I trial of intravesical bacillus Calmette-Guerin (BCG) in combination with systemic pembrolizumab was conducted in patients with high grade nonmuscle invasive bladder cancer who had persistent or recurrent disease after failing treatment with at least 2 courses of intravesical therapy (one of which had to contain BCG) or BCG followed by maintenance BCG. The primary objective was to determine the safety of this combination. Secondary end points included response to treatment at 19 weeks (end of treatment) and 3 months post treatment.
METHODS: A total of 12 patients were consented and 10 pa
